| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5824795 | Clinical Therapeutics | 2015 | 9 Pages |
Abstract
The nilotinib response rates were higher in chronic phase patients, and the most common adverse events were thrombocytopenia, myalgia, and headache.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Shabneez FCPS (Haematology), MBBS, Mohammad FCPS (Haematology), MBBS,